By Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a
… Read moreThe extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Lawsuits didn’t do it, public shaming didn’t do it, patients and doctors banding together to “free the data” couldn’t do it: For 22 years Myriad Genetics, one of the oldest genetic testing companies, has refused to make … Read more
By Health Day News
Testing for gene mutations linked to breast and ovarian cancer is rare among some Medicare patients who have the cancers and qualify for such tests, a new study finds.
Researchers analyzed data from 12 southeastern states … Read more
One of the most unsettling aspects of cancer is the unknown.
There is the unknown of what is in store for you if you receive a diagnosis of cancer. But on a larger scale, we all
While only 5 percent to 10 percent of cancers are caused by an inherited gene mutation, genetic testing may benefit people with a strong history of family cancer, an expert in genetics suggests.
This is especially true in families with … Read more
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more
Anna Hargrove learned she carries a genetic mutation that predisposes women toward breast and ovarian cancer at 27, which was no surprise given her family history.
Hargrove, cautious by nature, did what a lot of women with the mutation do: … Read more
As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer Institute… Read more
BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this … Read more
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).
Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more
The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more
A study published in October showed that high-grade serous ovarian carcinomas (HGSOC), which account for about 75 percent of ovarian cancers, originate with abnormal cells in the fallopian tubes an average of seven years before the disease develops. This understanding … Read more
Whether you’ve already been diagnosed, or you want to know your risk, health experts can test your DNA to determine your chances of developing cancer.
“The testing itself determines whether or not they have inherited this broken gene that could … Read more
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more
PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more
Myriad Genetics had been exclusively providing tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been … Read more
Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.
Results showed a median PFS of … Read more
Over the past 20 years, Nazneen Rahman has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers—work that has earned her scientific, popular, and even royal acclaim. But her latest accomplishment, and one … Read more
